Why is ERIS Lifescience falling/rising?

As of 30-Jun, ERIS Lifesciences Ltd is experiencing a slight increase in its stock price, currently at 1,680.70, with a change of 1.1 (0.07%) upwards. The stock has shown strong performance recently, gaining 3.59% over the last two days and opening with a gain of 2.1% today. It reached an intraday high of Rs 1714.95, although it also touched a low of Rs 1644.5 during the day. The stock has outperformed the Sensex over various periods, including a 64.04% return over the past year, indicating strong market performance. Positive factors contributing to this rise include high management efficiency, a low debt-to-EBITDA ratio, and significant institutional holdings, which suggest confidence in the company's fundamentals. However, there are concerns regarding long-term growth, as operating profit has only grown at an annual rate of 17.17% over the last five years, and profits have fallen by 10.1% despite the stock's strong returns.
In the broader market context, ERIS Lifesciences has outperformed the Sensex, which has only increased by 7.00% year-to-date, while ERIS has surged by 22.78% in the same period. This indicates that the stock is not only gaining traction among investors but is also benefiting from a favorable market environment compared to its benchmark. The stock's recent performance, combined with rising investor participation and liquidity, suggests a robust interest in the company, despite some underlying risks related to its long-term growth potential.